Azitra, Inc. (AZTR)
Develops genetically modified bacteria therapies to treat rare skin diseases.
$0.13+0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago-88.7%
The outlook
AZTR trades near the bottom of its 52-week range and sits below both its 50- and 200-day moving averages. Analyst coverage shows a wide gap, with the average price target implying substantial upside from current levels, though the overall sentiment leans bearish. The stock remains in a weak near-term trend despite the optimistic longer-term targets.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range2% of the way from its 52-week low to high
Price targetAvg target +496% vs current price
Analyst price target
~12-month · 2 analysts$0.78average target+495.7% vs now
Now $0.13
Low $0.55High $1.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$2.1M
52-wk high
$1.40
52-wk low
$0.10
50-day avg
$0.18
200-day avg
$0.27
Trailing P/E
—